Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.495    -0.475 (-11.96%)
Bid:
3.50
Ask:
3.895
Spread: 0.395 (11.286%)
Market Cap: £21.81m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Richard Warr

29 Jul 2015 07:00

RNS Number : 3521U
Immupharma PLC
29 July 2015
 

 

 

FOR IMMEDIATE RELEASE 29 JULY 2015

 

RICHARD WARR

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is truly saddened to announce that Richard Warr, Chairman, passed away late last week. 

Dimitri Dimitrou, Chief Executive Director said: "No words can truly convey the deep sadness we feel at Richard's untimely passing away. Richard will be remembered and missed by all of us at ImmuPharma. As a co-founder of ImmuPharma and a highly valued Chairman and friend, he provided the Board with insightful and considered advice and was instrumental in steering ImmuPharma into the successful Company we have today. All of us at ImmuPharma, associates and advisors who have worked closely with Richard over the years, extend our heartfelt thoughts and deepest sympathy to his wife and family."

 

ENDS

For further information please contact:

 

ImmuPharma plc

+ 44 (0) 20 7152 4080

 

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

 

+ 44 (0) 7721 413496

 

 

Panmure, Gordon & Co., NOMAD & Broker

+44 (0) 20 7886 2500

 

Hugh Morgan

Fred Walsh

Duncan Monteith

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDRBSDBGUI
Date   Source Headline
25th Jun 20261:20 pmRNS2026 RESULT OF ANNUAL GENERAL MEETING
25th Jun 20267:00 amRNSImmuPharma appoints Bachem for Kapiglucagon API
24th Jun 20267:00 amRNS-RUniversity of Murcia research relating to P140
4th Jun 20267:10 amRNS-RIncanthera plc – Corporate Update & Board Changes
2nd Jun 20267:00 amRNSNotice of AGM & Annual Report & Accounts
27th May 20267:00 amRNSFinal Results
5th May 20267:00 amRNSIMM initiatesIND-Enabling Program for Kapiglucagon
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNS-RChairman’s Open Letter to Shareholders
7th Apr 202611:45 amRNSResult of General Meeting and TVR
27th Mar 20267:00 amRNSP140 Program Update
23rd Mar 20267:00 amRNSResult of WRAP Retail Offer and TVR
19th Mar 20269:00 amRNSPublication of Circular
18th Mar 20267:00 amRNS-R‘Investor Meet Company’ presentation on 20 March
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
6th Jan 20264:11 pmRNSHolding(s) in Company
6th Jan 20267:00 amRNS-RAttending JPMorgan Conference & Biotech Showcase
24th Nov 20257:00 amRNSCorporate Update
4th Nov 20257:00 amRNSHolding(s) in Company
27th Oct 20257:00 amRNS-RIMMUPHARMA ATTENDING BIO-EUROPE
23rd Oct 20257:00 amRNSLaunch of Website; Corporate Update
13th Oct 20257:00 amRNSAppointment of Independent Non-Executive Director
6th Oct 20253:22 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSExercise of Warrants
11th Sep 20257:00 amRNSExercise of Warrants
1st Sep 20252:12 pmRNSAppointments of CSO and Head of R&D
1st Sep 20251:20 pmRNSImmuPharma Files New Patent Application for P140:
20th Aug 20251:36 pmRNSHolding(s) in Company
6th Aug 20257:00 amRNSInterim Results
12th Jun 202512:51 pmRNSResult of AGM
27th May 20253:13 pmRNSHolding(s) in Company
20th May 20257:00 amRNSNotice of AGM
19th May 20257:00 amRNSFinal Results
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
14th Mar 20257:00 amRNS-RIMM attending Bio-Europe Spring 17-19 March,Milan
13th Mar 20257:00 amRNSImmuPharma proves unique Mechanism of Action-P140
21st Feb 202511:36 amRNSHolding(s) in Company
13th Feb 20257:00 amRNS£2.91m fundraising; related party transactions
28th Jan 202512:57 pmRNSResponse to Share Price Movement
9th Jan 20257:00 amRNSBreakthrough Findings into Autoimmune Diseases
23rd Dec 20247:00 amRNSChange of Auditor
10th Dec 20242:36 pmRNSHolding(s) in Company
4th Dec 20247:00 amRNSAppointment of Company Secretary
9th Sep 20247:01 amRNSExtension of Warrants in Incanthera to 31 Mar 2025
9th Sep 20247:00 amRNSHalf-year Report
6th Aug 20241:41 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.